A phase III trial indicated that the combination of pembrolizumab with trastuzumab and chemotherapy improved progression-free survival (PFS) and overall survival (OS) in GC patients, particularly in those with a PD-L1 combined positive score (CPS) ≥1 (15–17). Here, CD274 is linked to gastric cancer.